- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
Topics to include DNA and RNA profiling and next-generation sequencing of tumors
The Symposium, which will be held at the
“About 1 in 8 U.S. women or about 12.4% will develop invasive breast
cancer over the course of her lifetime. Such staggering statistics make
breast cancer research and progress critical,” said Sandeep “Bobby”
Reddy MD, Chief Medical Officer,
Title: “Germline potentially pathogenic variants in breast cancer
intrinsic molecular subtypes are not associated with somatic TMB”
Presenting
Author:
Senior Author:
Contributors: Sandeep “Bobby” Reddy MD; Lori J.
Goldstein, MD;
Description: Comprehensive DNA and RNA
profiling of 270 patients revealed intrinsic molecular subtypes of
breast cancer have significantly distinct profiles of pathogenic
germline variants. However, despite some breast cancer subtypes having
higher frequency of germline pathogenic variants within DNA-damage
repair genes, there is little evidence that these patients have
subsequently higher mutational burden within their somatic genomes.
Key
Takeaway: Pathogenic germline variants in key DNA damage repair
genes such as BRCA1/2 are likely not adequate biomarkers for immune
checkpoint therapy response, but are potentially biomarkers of
differential tumorigenesis pathways.
Title: “Time-course DNA and RNA profiling of tumors from
intra-patient cross-over trial of sequential use of aromatase inhibitors”
Presenting
Author:
Senior Authors:
Contributors:
Description:
Early analysis from the ongoing NEOLETEXE trial examines a time-series
of biopsies taken while transitioning patients from steroidal to
non-steroidal aromatase inhibitors (AI) and vice versa. Acquired markers
of AI-therapy resistance, and potential markers of sequential therapy
sensitization, were explored. Two months after initial therapy,
mutational burden decreased and clonality increased, yet by 4mo
post-initialization mutations particularly in PIK3CA had repopulated.
Key
Takeaway: Switching AI therapies sequentially in a clinical study is
a model system to study differences in anti-tumor-effects of AIs. This
ongoing trial may lead to a novel strategy to resensitize tumors to
hormonal treatment and to elucidate the differences between steroidal
and non-steroidal AIs.
Title: “Identification of a neoantigen targeted by
tumor-infiltrating lymphocytes in a patient with Her2+ breast cancer”
Presenting
Author:
Senior Authors:
Contributors:
Description: In our study, we
identify tumor infiltrating T-cells (TILS) that recognize tumor specific
mutations (Neoepitopes) found by next-generation sequencing of breast
cancer tumors. These identified TILS are further immortalized and
characterized to bind the patient’s specific HLA alleles.
Key
Takeaway: Identification of TILS recognizing patient specific
neoepitopes allow development of personalized medicine in a pre-clinical
setting.
Since 1977, the San Antonio Breast Cancer Symposium mission has been to provide state-of-the-art information on breast cancer research. From a one-day regional conference, the Symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries. For more information visit: https://www.sabcs.org/2018-SABCS-sup-sup.
About
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005184/en/
Media:
NANT
jhodson@nantworks.com
Source: